SSG
DYN icon

Summit Securities Group’s Dyne Therapeutics DYN Stock Holding History

Summit Securities Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2K Buy
+1,268
New +$23.6K ﹤0.01% 662
2024
Q4 		– Sell
-1,000
Closed -$36K – 703
2024
Q3 		$36K Hold
1,000
– – 0.01% 265
2024
Q2 		$35K Hold
1,000
– – 0.01% 330
2024
Q1 		$28K Buy
+1,000
New +$22.6K ﹤0.01% 290

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Securities Group's DYN Position: Q2 2026 in Review

Summit Securities Group opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 1,268 shares worth $28.2K. The stake represents ﹤0.01% of the portfolio and ranks #662 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in DYN as recently as Q3 2024.

Summit Securities Group first reported a position in DYN in Q1 2024 and has held it in 4 quarters since. The position peaked at $36K in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Summit Securities Group held 1,268 shares of Dyne Therapeutics worth $28.2K as of Q2 2026.
  • Dyne Therapeutics was a new Summit Securities Group position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #662 holding.
  • Summit Securities Group first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Summit Securities Group's Dyne Therapeutics position peaked at $36K in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.